HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical usefulness of serum pepsinogen II in the management of Helicobacter pylori infection.

AbstractBACKGROUND:
Serum pepsinogen II (sPGII) levels are known to increase during Helicobacter pylori infection.
AIM:
To assess H. pylori infection and success of H. pylori therapy by means of sPGII levels.
METHODS:
sPGII levels were determined in 156 H. pylori-positive and 157 H. pylori-negative consecutive patients with dyspeptic symptoms. Additionally, sPGII determination was performed in 70 H. pylori-positive patients 2 months after H. pylori eradication therapy. In 29 of these 70 patients, gastroscopy was performed to evaluate the effect of H. pylori therapy on gastric activity.
RESULTS:
H. pylori-positive subjects demonstrated a significantly higher mean of sPGII levels than H. pylori-negative subjects (16.8 +/- 7.4 vs. 8.6 +/- 3.7 microg/l; p < 0.001). The best sPGII cut-off for predicting H. pylori infection was 9.93 microg/l (sensitivity 83%, specificity 73%). The best cut-off values to evaluate success of therapy were: sPGII of 9.47 microg/l, a sPGII variation level (difference between baseline and after therapy) of 4.54 microg/l, and a sPGII Deltavalue (sPGII variation divided by sPGII before therapy) of 25% (sensitivity 93%, specificity 91%).
CONCLUSIONS:
sPGII levels may be used as a reliable marker of H. pylori infection in the initial diagnosis as well as to evaluate H. pylori eradication and subsequent changes in gastric inflammation.
AuthorsFrancesco Di Mario, Ali Mahamat Moussa, Lucas Giovanni Cavallaro, Pietro Caruana, Roberta Merli, Simone Bertolini, Veronica Iori, Giulia Martina Cavestro, Nadia Dal Bò, Alberto Pilotto, Angelo Franzé, Gioacchino Leandro
JournalDigestion (Digestion) Vol. 70 Issue 3 Pg. 167-72 ( 2004) ISSN: 0012-2823 [Print] Switzerland
PMID15479977 (Publication Type: Journal Article)
CopyrightCopyright 2004 S. Karger AG, Basel.
Chemical References
  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Biomarkers
  • Pepsinogen C
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents (therapeutic use)
  • Anti-Ulcer Agents (therapeutic use)
  • Biomarkers (blood)
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Helicobacter Infections (blood, drug therapy)
  • Helicobacter pylori
  • Humans
  • Male
  • Middle Aged
  • Pepsinogen C (blood)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: